What are the latest funding news in the cell therapy market? (June 2026)
Download our beautiful pitch about the cell therapy market
In our cell therapy market deck, you will find everything you need to understand the market
Cell therapy fundraising in early 2026 was led by a mix of in vivo CAR-T platforms, public-market financings, and non-oncology regenerative medicine companies.
The 12 latest funding rounds we found reached about $650M in disclosed capital, with CREATE Medicines, Allogene Therapeutics, Oricell Therapeutics, and Cytotheryx representing the largest checks.
The market remained broad, with activity spanning oncology CAR-T, autoimmune cell therapy, cardiovascular regeneration, neurodegeneration, liver disease, kidney disease, and musculoskeletal disorders.
And if you want to better understand this new industry, you can download our pitch covering the cell therapy market.
Insights
- In vivo CAR-T stood out in the cell therapy market, with CREATE Medicines and Vivacta Bio alone raising more than $172M across May and April 2026.
- Public-market financings still mattered, as Allogene, BioRestorative, Ernexa, BrainStorm, and Lyell together represented more than $267M of disclosed cell therapy funding.
- Non-oncology cell therapy was not a niche side story, with Secretome, BrainStorm, BioRestorative, Regend, and Cytotheryx covering cardiac, ALS, spine, organ repair, and liver disease.
- China remained highly active in cell therapy funding, with Vivacta Bio, Regend Therapeutics, and Oricell Therapeutics raising more than $168M in disclosed capital.
- Large private rounds clustered around platforms with broad optionality, especially in vivo CAR-T, liver-cell manufacturing, and solid-tumor CAR-T development.
- Clinical-stage companies dominated the list, which suggests investors favored programs with human data or near-term regulatory milestones over very early discovery stories.
- The funding mix was unusually diverse, ranging from a $2M BrainStorm placement to Allogene's $200.4M public offering, showing very different capital needs inside cell therapy.
- Regenerative medicine deals were more disease-specific than oncology CAR-T deals, often tied to a single lead asset such as STM-01, NurOwn, BRTX-100, or hepatocyte-based liver therapy.
As this chart shows, and as featured in our cell therapy market deck, search interest in stem cell therapy has been rising steadily
Summary table of the latest funding deals in the cell therapy market as of June 2026
We define the cell therapy market as the market for cell-based medicinal products used as drugs to treat disease, including both approved products and major late-stage pipeline therapies.
We include living-cell products such as CAR-T, other engineered immune cells, and non-oncology cell-based drugs, along with their direct clinical use and revenue.
We exclude procedures like standard stem-cell transplants, simple minimally manipulated cell preparations used in surgery, and generic tools or equipment that are not specific to these therapies.
You can also read our detailed analysis to understand how funding activity in the cell therapy market has evolved over the last few years.
We also have a quarter-by-quarter analysis of funding activity in the market here.
Finally, you can check our complete list of fundraising deals for the cell therapy market (we update this list every quarter) as well as our ranking of the most funded startups.
| Name | When | Amount in $ | Round Type | Category |
|---|---|---|---|---|
| Secretome Therapeutics | 27 May 2026 | $30.0M | Series A | Non-oncology regenerative & cardiovascular cell therapy |
| Cellogen Therapeutics | 18 May 2026 | ~$2.3M | Strategic equity funding | Oncology CAR-T & hematology cell therapy |
| CREATE Medicines | 14 May 2026 | $122.0M | Series B | In vivo CAR-T, autoimmune & oncology cell therapy |
| Vivacta Bio | 29 April 2026 | >$50.0M | Series A & Series A+ | In vivo CAR-T, hematology & autoimmune cell therapy |
| Allogene Therapeutics | 16 April 2026 | $200.4M | Public offering | Allogeneic CAR-T, oncology & autoimmune cell therapy |
| Lyell Immunopharma | 9 March 2026 | $50.0M | Equity private placement tranche | Oncology CAR-T cell therapy |
| BrainStorm Cell Therapeutics | 26 February 2026 | $2.0M | Strategic private placement | Non-oncology neurodegenerative stem-cell therapy |
| BioRestorative Therapies | 13 February 2026 | $5.0M | Public offering | Non-oncology regenerative & musculoskeletal cell therapy |
| Regend Therapeutics | 11 February 2026 | ~$48M to $51M | Series C | Non-oncology organ-regeneration cell therapy |
| Ernexa Therapeutics | 6 February 2026 | $10.5M | Registered public offering | iPSC-derived oncology & autoimmune cell therapy |
| Oricell Therapeutics | 12 January 2026 | $70.0M | Series C1 | Solid-tumor oncology CAR-T cell therapy |
| Cytotheryx | 12 January 2026 | $60.0M | Series A | Non-oncology liver cell therapy |
All the latest funding deals during in the cell therapy market as of June 2026
Secretome Therapeutics raised $30.0M in May 2026.
When was it?
The deal was announced on 27 May 2026.
Who are they?
Secretome Therapeutics develops neonatal cardiac progenitor cell therapies, led by STM-01 for Duchenne-associated cardiomyopathy and other cardiomyopathies.
Geographical focus?
Secretome Therapeutics is based in Plano, Texas and is mainly focused on U.S. rare and serious cardiovascular disease programs.
Why do we include them in the cell therapy market?
Secretome Therapeutics belongs in the cell therapy market because STM-01 is a cellular therapy derived from neonatal cardiac progenitor cells, in the non-oncology cardiovascular cell therapy category.
What is the company stage?
Secretome Therapeutics is clinical-stage, with STM-01 moving toward Phase 2 and Phase 3 development.
How much did they raise?
Secretome Therapeutics raised $30.0M in this round.
What round is it?
The financing was a Series A round, with RA Capital Management as the sole investor.
Why did they raise?
Secretome Therapeutics raised to advance STM-01 toward pivotal trials in Duchenne-associated cardiomyopathy.
Cellogen Therapeutics raised about $2.3M in May 2026.
When was it?
The deal was announced on 18 May 2026.
Who are they?
Cellogen Therapeutics develops CAR-T and gene-therapy programs, including a bispecific dual-antigen CAR-T for cancers and blood disorders.
Geographical focus?
Cellogen Therapeutics is based in India and focuses on making advanced cell therapies more affordable for local patients.
Why do we include them in the cell therapy market?
Cellogen Therapeutics belongs in the cell therapy market because its lead programs are CAR-T cell therapies for oncology and hematology indications.
What is the company stage?
Cellogen Therapeutics is at pre-Phase 1 and clinical-entry stage, with human trials expected after regulatory approval.
How much did they raise?
Cellogen Therapeutics raised ₹20 crore, or about $2.3M.
What round is it?
The financing was described as a strategic equity investment rather than a named Series round.
Why did they raise?
Cellogen Therapeutics raised to advance CAR-T clinical programs, expand the gene-therapy pipeline, and strengthen GMP manufacturing and regulatory capabilities.
This chart, featured in our cell therapy market deck, compares the main business model options for cell therapy biotech companies
CREATE Medicines raised $122.0M in May 2026.
When was it?
The deal was announced on 14 May 2026.
Who are they?
CREATE Medicines develops in vivo CAR therapies that program immune cells inside the body using an mRNA-LNP platform.
Geographical focus?
CREATE Medicines is based in Cambridge, Massachusetts and is focused on U.S. development in autoimmune disease and oncology.
Why do we include them in the cell therapy market?
CREATE Medicines belongs in the cell therapy market because its platform creates engineered immune-cell therapies in vivo, especially in vivo CAR-T programs.
What is the company stage?
CREATE Medicines is clinical-stage, with more than 50 patients dosed across its in vivo CAR programs.
How much did they raise?
CREATE Medicines raised $122.0M in this round.
What round is it?
The financing was a Series B round co-led by Newpath Partners, ARCH Venture Partners, and Hatteras Venture Partners.
Why did they raise?
CREATE Medicines raised to move its CD19 in vivo CAR-T autoimmune program toward the clinic, expand CD19 x BCMA work, and continue oncology programs.
Vivacta Bio raised more than $50.0M in April 2026.
When was it?
The deal was announced on 29 April 2026.
Who are they?
Vivacta Bio develops in vivo CAR-T therapies, led by GT801 for hematologic malignancies and autoimmune diseases.
Geographical focus?
Vivacta Bio is focused on China, while also building global clinical and operating ambitions.
Why do we include them in the cell therapy market?
Vivacta Bio belongs in the cell therapy market because GT801 is a next-generation in vivo CAR-T therapy for hematology and autoimmune indications.
What is the company stage?
Vivacta Bio is early clinical-stage, with early human data reported at ASH 2025.
How much did they raise?
Vivacta Bio raised more than $50.0M across the combined financing.
What round is it?
The financing combined Series A and Series A+ rounds, led by Loyal Valley Capital and Decheng Capital respectively.
Why did they raise?
Vivacta Bio raised to advance GT801 clinical trials, support regulatory submissions, expand R&D, and accelerate global operations.
This chart, featured in our cell therapy market deck, shows how Legend Biotech is winning in cell therapy
Allogene Therapeutics raised $200.4M in April 2026.
When was it?
The deal was announced on 16 April 2026.
Who are they?
Allogene Therapeutics develops off-the-shelf allogeneic CAR-T therapies for cancer and autoimmune disease.
Geographical focus?
Allogene Therapeutics is based in South San Francisco and is building donor-derived CAR-T products for U.S. and global development.
Why do we include them in the cell therapy market?
Allogene Therapeutics belongs in the cell therapy market because its core business is allogeneic CAR-T product candidates.
What is the company stage?
Allogene Therapeutics is late clinical-stage, with pivotal oncology programs and autoimmune programs in development.
How much did they raise?
Allogene Therapeutics raised $200.4M in gross proceeds.
What round is it?
The financing was an underwritten public offering of common stock rather than a venture Series round.
Why did they raise?
Allogene Therapeutics raised to fund clinical trials, R&D, G&A, capital expenditures, and general corporate purposes.
Lyell Immunopharma raised $50.0M in March 2026.
When was it?
The deal was announced on 9 March 2026.
Who are they?
Lyell Immunopharma develops next-generation CAR-T therapies for hematologic malignancies and solid tumors.
Geographical focus?
Lyell Immunopharma is based in South San Francisco and is mainly focused on U.S. oncology development.
Why do we include them in the cell therapy market?
Lyell Immunopharma belongs in the cell therapy market because its pipeline is built around CAR-T cell therapies.
What is the company stage?
Lyell Immunopharma is late clinical-stage, with ronde-cel in pivotal clinical development for relapsed or refractory large B-cell lymphoma.
How much did they raise?
Lyell Immunopharma raised $50.0M in this tranche.
What round is it?
The financing was the second tranche of a broader $100.0M equity private placement.
Why did they raise?
Lyell Immunopharma raised after a clinical milestone to extend runway and support working capital and CAR-T development.
In our cell therapy market deck, we identify pain points entrepreneurs should prioritize
BrainStorm Cell Therapeutics raised $2.0M in February 2026.
When was it?
The deal was announced on 26 February 2026.
Who are they?
BrainStorm Cell Therapeutics develops autologous adult stem-cell therapies for neurodegenerative diseases, led by NurOwn for ALS.
Geographical focus?
BrainStorm Cell Therapeutics is mainly focused on U.S. clinical development for ALS.
Why do we include them in the cell therapy market?
BrainStorm Cell Therapeutics belongs in the cell therapy market because NurOwn uses autologous mesenchymal stem cells induced to secrete neurotrophic factors.
What is the company stage?
BrainStorm Cell Therapeutics is late clinical-stage, with a completed Phase 3 and a planned Phase 3b confirmatory study.
How much did they raise?
BrainStorm Cell Therapeutics raised $2.0M in total during February 2026.
What round is it?
The financing was a strategic private placement.
Why did they raise?
BrainStorm Cell Therapeutics raised to support near-term regulatory and clinical objectives for NurOwn.
BioRestorative Therapies raised $5.0M in February 2026.
When was it?
The deal was announced on 13 February 2026.
Who are they?
BioRestorative Therapies develops cell-based therapies, led by BRTX-100 for painful lumbosacral disc disorders.
Geographical focus?
BioRestorative Therapies is based in New York and is focused on U.S. regenerative medicine development.
Why do we include them in the cell therapy market?
BioRestorative Therapies belongs in the cell therapy market because BRTX-100 is a therapeutic autologous mesenchymal stem-cell product.
What is the company stage?
BioRestorative Therapies is late clinical-stage in regenerative medicine.
How much did they raise?
BioRestorative Therapies raised $5.0M in gross proceeds.
What round is it?
The financing was a public offering of common stock and pre-funded warrants with accompanying warrants.
Why did they raise?
BioRestorative Therapies raised to fund BRTX-100 clinical trials, ThermoStem preclinical R&D, working capital, and corporate needs.
This market map, featured in our cell therapy market deck, highlights top companies and startups in the cell therapy market
Regend Therapeutics raised about $48M to $51M in February 2026.
When was it?
The deal was announced on 11 February 2026.
Who are they?
Regend Therapeutics develops stem and progenitor-cell regenerative therapies for organ repair, including lung and kidney disease programs.
Geographical focus?
Regend Therapeutics is mainly focused on China, with programs in COPD, IPF, and chronic kidney disease.
Why do we include them in the cell therapy market?
Regend Therapeutics belongs in the cell therapy market because its core products are stem and progenitor-cell therapeutic products for organ regeneration.
What is the company stage?
Regend Therapeutics is clinical-stage and clinical-translation stage, including a kidney progenitor cell therapy that initiated Phase I trials in China.
How much did they raise?
Regend Therapeutics raised RMB 350M, or roughly $48M to $51M depending on exchange rates.
What round is it?
The financing was a Series C round.
Why did they raise?
Regend Therapeutics raised to accelerate clinical translation of core stem and progenitor-cell products and prepare for larger-scale commercialization.
Ernexa Therapeutics raised $10.5M in February 2026.
When was it?
The deal was announced on 6 February 2026.
Who are they?
Ernexa Therapeutics develops engineered iPSC-derived induced mesenchymal stem-cell therapies, led by ERNA-101 for ovarian cancer.
Geographical focus?
Ernexa Therapeutics is U.S.-based, with an initial focus on advanced cancer and autoimmune disease.
Why do we include them in the cell therapy market?
Ernexa Therapeutics belongs in the cell therapy market because its candidates are allogeneic iPSC-derived cell therapies.
What is the company stage?
Ernexa Therapeutics is preclinical and IND-enabling stage, with ERNA-101 advancing toward first-in-human trials.
How much did they raise?
Ernexa Therapeutics expected $10.5M in gross proceeds from the offering.
What round is it?
The financing was a best-efforts registered public offering.
Why did they raise?
Ernexa Therapeutics raised to advance development programs, fund working capital, and support general corporate purposes.
This chart, featured in our cell therapy market deck, shows annual funding in cell therapy startups
Oricell Therapeutics raised $70.0M in January 2026.
When was it?
The deal was announced on 12 January 2026.
Who are they?
Oricell Therapeutics develops CAR-T therapies for solid tumors and blood cancers, including GPC3-targeted CAR-T for hepatocellular carcinoma.
Geographical focus?
Oricell Therapeutics is based in Shanghai and is building global development ambitions.
Why do we include them in the cell therapy market?
Oricell Therapeutics belongs in the cell therapy market because its pipeline is built around CAR-T cell therapies for solid tumors and blood cancers.
What is the company stage?
Oricell Therapeutics is clinical-stage and approaching pivotal development, with Ori-C101 positioned for a registrational pivotal trial.
How much did they raise?
Oricell Therapeutics raised $70.0M in the initial closing.
What round is it?
The financing was a Series C1 round.
Why did they raise?
Oricell Therapeutics raised to accelerate global expansion, clinical development, technology capabilities, and commercialization preparation.
Cytotheryx raised $60.0M in January 2026.
When was it?
The deal was announced on 12 January 2026, with a follow-up investor announcement on 16 January 2026.
Who are they?
Cytotheryx develops liver-cell therapies, including scalable human hepatocyte production, bioartificial liver support, and universal liver cells for transplantation.
Geographical focus?
Cytotheryx is a Mayo Clinic spinout based in Rochester, Minnesota and is focused on liver disease.
Why do we include them in the cell therapy market?
Cytotheryx belongs in the cell therapy market because the company is developing cell-based treatments using clinically relevant human hepatocytes.
What is the company stage?
Cytotheryx is preclinical-stage.
How much did they raise?
Cytotheryx raised $60.0M in this round.
What round is it?
The financing was a Series A round, alongside separate debt financing.
Why did they raise?
Cytotheryx raised to move liver-cell therapy programs toward the clinic and scale GMP manufacturing.
Related blog posts
- How strong is fundraising in the cell therapy market right now?
- What is the latest news in the cell therapy market?
- What is the true size of the cell therapy market?
- How funding activity has evolved in the cell therapy market
- What are the key fundraising trends in the cell therapy market?
- A complete list of funding deals in the cell therapy market
- Which companies have raised the most funding in the cell therapy market?
- Which companies are the most valued in the cell therapy market?
- A complete list of business models in the cell therapy market
